AIM
ANIK icon

Acrospire Investment Management’s Anika Therapeutics ANIK Stock Holding History

Acrospire Investment Management’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-877
Closed -$43K – 75
2017
Q2 		$43K Buy
+877
New +$40.4K 0.04% 986
2016
Q3 		– Sell
-1,308
Closed -$70K – 1959
2016
Q2 		$70K Sell
1,308
-800
-38% -$37.7K 0.05% 787
2016
Q1 		$94K Buy
+2,108
New +$85.5K 0.07% 360

Other funds holding ANIK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AAM
AMI Asset Management Los Angeles, California $1.74B AUM 26.89% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
TAM
THB Asset Management Norwalk, Connecticut $440M AUM 59.59% 1-Year Est. Return

Acrospire Investment Management's ANIK Position: Q3 2017 in Review

Acrospire Investment Management sold out of Anika Therapeutics (ANIK) in Q3 2017, closing a stake of 877 shares — an estimated $43K sold.

Acrospire Investment Management first reported a position in ANIK in Q1 2016 and held it in 3 quarters. The position peaked at $94K in Q1 2016. 166 funds tracked by Wall St. Rank hold ANIK as of Q3 2017.

  • Acrospire Investment Management reported no remaining Anika Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 877 Anika Therapeutics shares in Q3 2017, an estimated $43K.
  • Acrospire Investment Management first reported a position in Anika Therapeutics in Q1 2016 and held it in 3 quarters.
  • Acrospire Investment Management's Anika Therapeutics position peaked at $94K in Q1 2016.
  • 166 funds tracked by Wall St. Rank held Anika Therapeutics as of Q3 2017.

Based on Acrospire Investment Management's 13F filing for Q3 2017, filed 26 Oct 2017.